Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8741 |
High Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.8741 |
High Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8652 |
High Similarity |
NPD2800 |
Approved |
0.8623 |
High Similarity |
NPD6651 |
Approved |
0.8514 |
High Similarity |
NPD7411 |
Suspended |
0.8477 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.84 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.84 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.838 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.838 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8356 |
Intermediate Similarity |
NPD2534 |
Approved |
0.8356 |
Intermediate Similarity |
NPD2533 |
Approved |
0.8356 |
Intermediate Similarity |
NPD2532 |
Approved |
0.8333 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.8322 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8322 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8278 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8264 |
Intermediate Similarity |
NPD1243 |
Approved |
0.8239 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8224 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.8207 |
Intermediate Similarity |
NPD3750 |
Approved |
0.82 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.8182 |
Intermediate Similarity |
NPD2796 |
Approved |
0.8153 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.8117 |
Intermediate Similarity |
NPD3749 |
Approved |
0.8085 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8052 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.8041 |
Intermediate Similarity |
NPD6799 |
Approved |
0.8041 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8028 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.8028 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.8014 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD920 |
Approved |
0.8 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7974 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7972 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7962 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7959 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7943 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7933 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7922 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7888 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7871 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7862 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7862 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7852 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7843 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7838 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7817 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7808 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7808 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7799 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7799 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7748 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7707 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7688 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7687 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7687 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7683 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7681 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7669 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7654 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7647 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7635 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7626 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7595 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7593 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7593 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7593 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7589 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7569 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7561 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7548 |
Intermediate Similarity |
NPD3226 |
Approved |
0.753 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7516 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7515 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7515 |
Intermediate Similarity |
NPD7472 |
Approved |
0.75 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.75 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD919 |
Approved |
0.75 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7485 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7485 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.747 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7468 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7465 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7455 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7453 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7425 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7421 |
Intermediate Similarity |
NPD5402 |
Approved |
0.74 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7383 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7381 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7368 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7329 |
Intermediate Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.7329 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.731 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7292 |
Intermediate Similarity |
NPD2798 |
Approved |
0.7278 |
Intermediate Similarity |
NPD6585 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7262 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7233 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.723 |
Intermediate Similarity |
NPD4307 |
Phase 2 |
0.7226 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7225 |
Intermediate Similarity |
NPD4287 |
Approved |
0.7222 |
Intermediate Similarity |
NPD3267 |
Approved |
0.7222 |
Intermediate Similarity |
NPD3266 |
Approved |
0.7211 |
Intermediate Similarity |
NPD411 |
Approved |
0.7208 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7205 |
Intermediate Similarity |
NPD4288 |
Approved |
0.7203 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7192 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.719 |
Intermediate Similarity |
NPD2654 |
Approved |
0.7181 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7181 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7175 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.7159 |
Intermediate Similarity |
NPD4360 |
Phase 2 |
0.7159 |
Intermediate Similarity |
NPD4363 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7133 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7125 |
Intermediate Similarity |
NPD5890 |
Approved |
0.7125 |
Intermediate Similarity |
NPD5889 |
Approved |
0.7122 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7114 |
Intermediate Similarity |
NPD943 |
Approved |
0.7105 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7105 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7105 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7105 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7095 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7091 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7089 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.707 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7067 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7063 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7045 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD5049 |
Phase 3 |
0.7022 |
Intermediate Similarity |
NPD4361 |
Phase 2 |
0.7022 |
Intermediate Similarity |
NPD4362 |
Clinical (unspecified phase) |
0.7021 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7 |
Intermediate Similarity |
NPD1729 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.6986 |
Remote Similarity |
NPD1164 |
Approved |
0.698 |
Remote Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.6968 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6964 |
Remote Similarity |
NPD2403 |
Approved |
0.6959 |
Remote Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.6948 |
Remote Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.6948 |
Remote Similarity |
NPD6005 |
Phase 3 |
0.6948 |
Remote Similarity |
NPD6004 |
Phase 3 |
0.6948 |
Remote Similarity |
NPD6002 |
Phase 3 |
0.6948 |
Remote Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.6948 |
Remote Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.6946 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6939 |
Remote Similarity |
NPD1019 |
Discontinued |
0.6923 |
Remote Similarity |
NPD7003 |
Approved |
0.6923 |
Remote Similarity |
NPD17 |
Approved |
0.6919 |
Remote Similarity |
NPD6104 |
Discontinued |
0.6919 |
Remote Similarity |
NPD7584 |
Approved |
0.6905 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6899 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6892 |
Remote Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD2354 |
Approved |
0.6867 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6867 |
Remote Similarity |
NPD5537 |
Clinical (unspecified phase) |
0.6853 |
Remote Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.6846 |
Remote Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.6839 |
Remote Similarity |
NPD8313 |
Approved |
0.6839 |
Remote Similarity |
NPD8312 |
Approved |
0.6795 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6786 |
Remote Similarity |
NPD1398 |
Phase 1 |
0.6786 |
Remote Similarity |
NPD7199 |
Phase 2 |
0.6784 |
Remote Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.6781 |
Remote Similarity |
NPD1481 |
Phase 2 |
0.6776 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6774 |
Remote Similarity |
NPD4476 |
Approved |
0.6774 |
Remote Similarity |
NPD4477 |
Approved |
0.6765 |
Remote Similarity |
NPD7784 |
Clinical (unspecified phase) |
0.6761 |
Remote Similarity |
NPD7340 |
Approved |
0.6732 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6731 |
Remote Similarity |
NPD2355 |
Clinical (unspecified phase) |
0.6731 |
Remote Similarity |
NPD2353 |
Approved |
0.6728 |
Remote Similarity |
NPD1653 |
Approved |
0.6727 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6723 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6713 |
Remote Similarity |
NPD7644 |
Approved |
0.6712 |
Remote Similarity |
NPD1535 |
Discovery |
0.6712 |
Remote Similarity |
NPD1201 |
Approved |
0.671 |
Remote Similarity |
NPD651 |
Clinical (unspecified phase) |
0.6707 |
Remote Similarity |
NPD6971 |
Discontinued |
0.6706 |
Remote Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.6702 |
Remote Similarity |
NPD7585 |
Approved |
0.669 |
Remote Similarity |
NPD4626 |
Approved |
0.669 |
Remote Similarity |
NPD1778 |
Approved |
0.6687 |
Remote Similarity |
NPD2296 |
Approved |
0.6686
|
Remote Similarity |
NPD7177 |
Discontinued |